Telo Financial Statements From 2010 to 2024
| 3D0A Stock | EUR 0.04 0.01 28.57% |
Check Telo Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telo Genomics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Telo financial statements analysis is a perfect complement when working with Telo Genomics Valuation or Volatility modules.
Telo |
Telo Genomics Corp Company Shares Owned By Insiders Analysis
Telo Genomics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Telo Genomics Shares Owned By Insiders | 6.52 % |
Most of Telo Genomics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telo Genomics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 6.524% of Telo Genomics Corp are shares owned by insiders. This is 57.02% lower than that of the Healthcare sector and 57.58% lower than that of the Diagnostics & Research industry. The shares owned by insiders for all Germany stocks is 35.34% higher than that of the company.
Telo Genomics Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Telo Genomics's current stock value. Our valuation model uses many indicators to compare Telo Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Telo Genomics competition to find correlations between indicators driving Telo Genomics's intrinsic value. More Info.Telo Genomics Corp is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telo Genomics' earnings, one of the primary drivers of an investment's value.About Telo Genomics Financial Statements
Telo Genomics stakeholders use historical fundamental indicators, such as Telo Genomics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Telo Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Telo Genomics' assets and liabilities are reflected in the revenues and expenses on Telo Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Telo Genomics Corp. Please read more on our technical analysis and fundamental analysis pages.
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. Telo Genomics Corp. was incorporated in 2011 and is headquartered in Toronto, Canada. TELO GENOMICS operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Telo Stock
Telo Genomics financial ratios help investors to determine whether Telo Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Telo with respect to the benefits of owning Telo Genomics security.